Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
This study was designed to test the hypotheses that furosemide directly causes relaxation in human fetal airway and that delivery of loop diuretics to either the adventitial or epithelial surface of newborn mouse airway results in equivalent relaxation. Isometric tension changes were measured in human fetal (11-16 wk) trachea and mainstem bronchus rings exposed to furosemide (300 M) or saline after acetylcholine or leukotriene D 4 constriction. Significant decreases in isometric tension to furosemide were demonstrated after constriction with acetylcholine or leukotriene D 4 . To examine the site of effect and mimic aerosolized and systemic administration, furosemide (3-300 M) and bumetanide (0.3-30 M) were applied separately to epithelial and adventitial surfaces of newborn mouse airways. No differences in airway diameter changes to epithelial or adventitial furosemide or bumetanide were observed, but a 10-fold difference in potency was found. In summary, human fetal airway relaxed to furosemide when constricted with either neurotransmitter or inflammatory mediator in vitro. Further, no differences in relaxation to equimolar epithelial and adventitial furosemide were observed in isolated newborn mouse airway. Taken together, this provides evidence that furosemide has a direct, nonepithelial-dependent effect on airway smooth muscle tone. Systemically administered furosemide improves pulmonary mechanics and gas exchange in infants with chronic lung disease independent of its diuretic effects (1, 2). Studies demonstrating a reduction of bronchoconstrictive responses in pediatric (3) and adult asthmatics (4, 5) with aerosolized furosemide further support the notion that a nondiuretic effect may produce improvements in pulmonary function. Indeed, the in vitro airway relaxation to furosemide that is observed in animal models (6 -8) suggests that there may be a direct effect on airway smooth muscle.However, a bronchodilatory response to inhaled furosemide is not consistently observed in infants with chronic lung disease (9, 10). Although aerosolized administration of furosemide could minimize systemic effects while producing localized bronchodilation, it is not widely accepted that inhaled furosemide has therapeutic efficacy during acute bronchoconstriction. Taken together, it is presently unclear whether these inconsistent results are because of species differences or inadequate concentrations of drug that reach the airway with aerosolized treatment, or because furosemide in fact does not act via a mechanism of direct airway smooth muscle relaxation (11). Therefore, the potential relevance of previous in vitro animal findings requires validation by the study of human airway response (12), with the first objective to test the hypothesis that furosemide causes direct relaxation of human fetal airway.In addition to demonstrating a direct relaxing effect on airway smooth muscle, further support for the bronchodilatory response to furosemide via aerosolization would require evidence that mechanisms can be activated from th...
This study was designed to test the hypotheses that furosemide directly causes relaxation in human fetal airway and that delivery of loop diuretics to either the adventitial or epithelial surface of newborn mouse airway results in equivalent relaxation. Isometric tension changes were measured in human fetal (11-16 wk) trachea and mainstem bronchus rings exposed to furosemide (300 M) or saline after acetylcholine or leukotriene D 4 constriction. Significant decreases in isometric tension to furosemide were demonstrated after constriction with acetylcholine or leukotriene D 4 . To examine the site of effect and mimic aerosolized and systemic administration, furosemide (3-300 M) and bumetanide (0.3-30 M) were applied separately to epithelial and adventitial surfaces of newborn mouse airways. No differences in airway diameter changes to epithelial or adventitial furosemide or bumetanide were observed, but a 10-fold difference in potency was found. In summary, human fetal airway relaxed to furosemide when constricted with either neurotransmitter or inflammatory mediator in vitro. Further, no differences in relaxation to equimolar epithelial and adventitial furosemide were observed in isolated newborn mouse airway. Taken together, this provides evidence that furosemide has a direct, nonepithelial-dependent effect on airway smooth muscle tone. Systemically administered furosemide improves pulmonary mechanics and gas exchange in infants with chronic lung disease independent of its diuretic effects (1, 2). Studies demonstrating a reduction of bronchoconstrictive responses in pediatric (3) and adult asthmatics (4, 5) with aerosolized furosemide further support the notion that a nondiuretic effect may produce improvements in pulmonary function. Indeed, the in vitro airway relaxation to furosemide that is observed in animal models (6 -8) suggests that there may be a direct effect on airway smooth muscle.However, a bronchodilatory response to inhaled furosemide is not consistently observed in infants with chronic lung disease (9, 10). Although aerosolized administration of furosemide could minimize systemic effects while producing localized bronchodilation, it is not widely accepted that inhaled furosemide has therapeutic efficacy during acute bronchoconstriction. Taken together, it is presently unclear whether these inconsistent results are because of species differences or inadequate concentrations of drug that reach the airway with aerosolized treatment, or because furosemide in fact does not act via a mechanism of direct airway smooth muscle relaxation (11). Therefore, the potential relevance of previous in vitro animal findings requires validation by the study of human airway response (12), with the first objective to test the hypothesis that furosemide causes direct relaxation of human fetal airway.In addition to demonstrating a direct relaxing effect on airway smooth muscle, further support for the bronchodilatory response to furosemide via aerosolization would require evidence that mechanisms can be activated from th...
Exercise-induced bronchoconstriction (EIB) is exaggerated constriction of the airways usually soon after cessation of exercise. This is most often a response to airway dehydration in the presence of airway inflammation in a person with a responsive bronchial smooth muscle. Severity is related to water content of inspired air and level of ventilation achieved and sustained. Repetitive hyperpnea of dry air during training is associated with airway inflammatory changes and remodeling. A response during exercise that is related to pollution or allergen is considered EIB. Ozone and particulate matter are the most widespread pollutants of concern for the exercising population; chronic exposure can lead to new-onset asthma and EIB. Freshly generated emissions particulate matter less than 100 nm is most harmful. Evidence for acute and long-term effects from exercise while inhaling high levels of ozone and/or particulate matter exists. Much evidence supports a relationship between development of airway disorders and exercise in the chlorinated pool. Swimmers typically do not respond in the pool; however, a large percentage responds to a dry air exercise challenge. Studies support oxidative stress mediated pathology for pollutants and a more severe acute response occurs in the asthmatic. Winter sport athletes and swimmers have a higher prevalence of EIB, asthma and airway remodeling than other athletes and the general population. Because of fossil fuel powered ice resurfacers in ice rinks, ice rink athletes have shown high rates of EIB and asthma. For the athlete training in the urban environment, training during low traffic hours and in low traffic areas is suggested.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.